Trial Profile
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms TROP
- 15 Apr 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2011 Actual initiation date (Oct 2009) added as reported by ClinicalTrials.gov.
- 20 Jul 2011 Planned end date changed from 1 Apr 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.